

IN THE CLAIMS

The status of each claim in the present application is listed below.


Please amend the claims as follows:

Claim 1 (Currently Amended): An active substance combination, comprising:  
~~characterized in that it comprises:~~

- (A) at least one compound with neuropeptide Y (NPY) -receptor affinity, and
- (B) at least one compound with 5-HT<sub>6</sub> receptor affinity.

Claim 2 (Currently Amended): The combination according to claim 1, wherein  
~~characterized in that~~ as component (A) at least one compound with neuropeptide Y5 (NPY5)  
-receptor affinity is present.

Claim 3 (Currently Amended): The combination according to claim 1 or 2, wherein  
~~characterized in that~~ as component (A) at least one compound is present, which is a selected  
~~from the group consisting of the~~ 1,4-disubstituted piperidine compound ~~compounds~~ of  
general formula (Ia)



wherein  $R^{1a}$ ,  $R^{2a}$ ,  $R^{3a}$ ,  $R^{4a}$  are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro, cyano,  $-OR^{12a}$ ,  $-O-(C=O)R^{13a}$ ,  $-(C=O)-OR^{13a}$ ,  $-SR^{14a}$ ,  $-SOR^{14a}$ ,  $-SO_2R^{14a}$ ,  $-NH-SO_2R^{14a}$ ,  $-SO_2NH_2$  and  $-NR^{15a}R^{16a}$  moiety,

$R^{5a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical,

$R^{6a}$ ,  $R^{7a}$ ,  $R^{8a}$ ,  $R^{9a}$  are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano and a  $COOR^{17a}$  moiety,

$A^a$  represents a bridge member  $-CHR^{18a}-$  or  $-CHR^{18a}-CH_2-$ ,

$B^a$  represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, a  $COOR^{19a}$ -moiety, a  $-(C=O)R^{20a}$ -moiety, or a  $-CH_2OR^{23a}$ -moiety,

$R^{10a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{11a}$  represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, or an optionally at least mono substituted aryl- or heteroaryl radical, which may

be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono- substituted mono- or polycyclic ringsystem, or

$R^{10a}$  and  $R^{11a}$  together with the bridging nitrogen atom form an optionally at least mono-substituted, saturated, unsaturated or aromatic heterocyclic ring that may contain at least one further heteroatom as a ring member and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem,

$R^{12a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{13a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono- substituted mono- or polycyclic ring-system,

$R^{14a}$  represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{15a}$  and  $R^{16a}$  each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

or  $R^{15a}$  and  $R^{16a}$  together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

$R^{17a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical,

which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{18a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{19a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{20a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or a  $NR^{21a}R^{22a}$ -moiety,

$R^{21a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,


$R^{22a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at

least mono-substituted cycloaliphatic radical, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{23a}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, which may comprise at least one heteroatom as a chain member, or a- (C=O) $R^{13a}$ -moiety,

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, ~~preferably enantiomers or diastereomers~~, in any mixing ratio, or salts, ~~preferably physiologically acceptable salts thereof, or corresponding solvates.~~

Claim 4 (Currently Amended): The combination according to claim 1 or 2 ~~any one of the claims 1 to 3, wherein characterized in that~~ as component (B) at least one compound ~~[[ist]]~~ is present, which is ~~a selected from the group consisting of the~~ benzoxazinone-derived sulfonamide compound ~~compounds~~ of general formula (Ib)



(1b)

wherein

$R^{1b}$ ,  $R^{2b}$ ,  $R^{3b}$ ,  $R^{4b}$  are each independently selected from the group consisting of hydrogen, halogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ringsystem, a nitro, cyano,  $-OR^{10b}$ ,  $-O(C=O)R^{11b}$ ,  $-(C=O)OR^{11b}$ ,  $-SR^{12b}$ ,  $-SOR^{12b}$ ,  $-SO_2R^{12b}$ ,  $-NH-SO_2R^{12b}$ ,  $-SO_2NH_2$  and a  $-NR^{13b}R^{14b}$  moiety,



$R^{5b}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical,

$R^{6b}$ ,  $R^{7b}$ ,  $R^{8b}$ ,  $R^{9b}$  are each independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, a cyano group and a  $COOR^{15b}$  moiety,

$W^b$  represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

an optionally at least mono-substituted aryl or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene or alkenylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

a  $NR^{16b}R^{17b}$ -moiety or

a  $COR^{18b}$ -moiety,

$R^{10b}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono-

or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{11b}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono- substituted mono- or polycyclic ring-system,

$R^{12b}$  represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{13b}$  and  $R^{14b}$  each are independently selected from the group consisting of hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical, which may be bonded

via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,


or  $R^{13b}$  and  $R^{14b}$  together with the bridging nitrogen atom form a saturated, unsaturated or aromatic heterocyclic ring, which may be at least mono-substituted and/or contain at least one further heteroatom as a ring member,

$R^{15b}$  represents hydrogen, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic radical or an optionally at least mono-substituted aryl- or heteroaryl radical, which may be bonded via an optionally at least mono-substituted alkylene group and/or may be condensed with an optionally at least mono-substituted mono- or polycyclic ring-system,

$R^{16b}$  represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical,

$R^{17b}$  represents an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, and

$R^{18}$  represents an optionally at least mono-substituted aryl radical optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, ~~or a solvate~~, respectively, and compounds derived from sulfonamide of general formula (Ic),



(Ic)

wherein  $R^{1c}$  represents hydrogen, an optionally at least mono-substituted, linear or branched alkyl radical, an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted benzyl radical,

$R^{2c}$  represents a  $-NR^{4c}R^{5c}$  moiety or a saturated or unsaturated, optionally at least mono-substituted, optionally at-least one heteroatom as ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing mono- or bicyclic cycloaliphatic ringsystem,

$R^{3c}$  represents hydrogen or an optionally at least mono-substituted, linear or branched alkyl radical,


$R^{4c}$  and  $R^{5c}$ , identical or different, represent hydrogen or an optionally at least mono-substituted, linear or branched alkyl radical, or

$R^{4c}$  and  $R^{5c}$  together with the bridging nitrogen atom form an optionally at least mono-substituted, saturated or unsaturated heterocyclic ring, which may contain at least one further heteroatom as a ring member and/or may be condensed with a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing mono- or bicyclic cycloaliphatic ringsystem,

A<sup>c</sup> represents an optionally at least mono-substituted mono- or polycyclic aromatic ringsystem, which may be bonded via an optionally at least mono-substituted alkylene-, an optionally at least mono-substituted alkenylene-or an optionally at least mono-substituted alkynylene group and/or may contain at least one heteroatom as a ring member in one or more of its rings,

nc represents 0,1, 2,3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a corresponding physiologically acceptable salt ~~or a corresponding solvate~~, and compounds of general formula (Id)



(Id)

R<sup>1d</sup> represents a -NR<sup>8d</sup>R<sup>9d</sup> radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

$R^{2d}$ ,  $R^{3d}$ ,  $R^{5d}$ ,  $R^{6d}$  and  $R^{7d}$ , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl or an optionally at least mono-substituted heteroaryl radical,

$R^{4d}$  is hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

$R^{8d}$  and  $R^{9d}$ , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or


$R^{8d}$  and  $R^{9d}$  together with bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,

$A^d$  represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

and

$n$  is 0, 1, 2, 3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, ~~or a corresponding solvate thereof,~~  
and compounds derived from sulfonamide of general formula (Ie)



wherein

wherein

$R^{1e}$  represents an  $-NR^{8e}R^{9e}$  radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may optionally contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,

$R^{2e}$ ,  $R^{3e}$ ,  $R^{4e}$ ,  $R^{6e}$  and  $R^{7e}$ , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical or an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted heteroaryl radical,

$R^{5e}$  represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

$R^{8e}$  and  $R^{9e}$ , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or


$R^{8e}$  and  $R^{9e}$  together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, mono- or bicyclic cycloaliphatic ring system which may optionally contain at least one heteroatom as a ring member,

$A^e$  represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

and

$n$  is 0, 1, 2, 3 or 4;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, at any mixture ratio, or a corresponding, physiologically acceptable salt, ~~or a corresponding solvate~~, and compounds derived from sulfonamide of general formula (If)



(If)

wherein



$R^{1f}$  represents a  $-NR^{8f}R^{9f}$  radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

$R^{2f}$ ,  $R^{3f}$ ,  $R^{4f}$ ,  $R^{5f}$  and  $R^{7f}$ , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted heteroaryl radical,

$R^{6f}$  represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

$R^{8f}$  and  $R^{9f}$ , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or


$R^{8f}$  and  $R^{9f}$ , together with the bridging nitrogen atom, form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one further heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

$A^f$  represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings

and

$nf$  is 0, 1, 2, 3 or 4;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, at any mixture ratio, or a corresponding, physiologically acceptable salt, ~~or a corresponding solvate~~, and compounds derived from sulfonamide of general formula (Ig)



wherein

$R^{1g}$  is a  $-NR^{8g}R^{9g}$  radical or a saturated or unsaturated, optionally at least mono-substituted cycloaliphatic radical, which may optionally contain at least one heteroatom as a ring member and which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system ~~system which~~ system which may optionally contain at least one heteroatom as a ring member,

$R^{2g}$ ,  $R^{3g}$ ,  $R^{4g}$ ,  $R^{5g}$  and  $R^{6g}$ , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical, or an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted heteroaryl radical,

$R^{7g}$  represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

$R^{8g}$  and  $R^{9g}$ , identical or different, represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,


or

$R^{8g}$  and  $R^{9g}$  together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,

$A^g$  represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

ng is 0,1, 2,3 or 4;

optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, at any mixture ratio, or a corresponding, physiologically acceptable salt, ~~or a corresponding solvate~~ and compounds derived from sulfonamide of general formula (Ih)



(Ih)

wherein

$R^{1h}$  represents a  $-NR^{7h}R^{8h}$  radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

$R^{2h}$ ,  $R^{3h}$ ,  $R^{4h}$ ,  $R^{5h}$  and  $R^{6h}$ , identical or different, each represent hydrogen, halogen, cyano, nitro, a linear or branched alkyl radical, a linear or branched alkenyl radical, a linear or branched alkenyl radical, a linear or branched alkoxy radical, a linear or branched alkylthio radical, hydroxy, trifluoromethyl, a cycloalkyl radical, a cycloalkenyl radical, an alkylcarbonyl radical, a phenylcarbonyl or a  $-NR^{9h}R^{10h}$  group,

$R^{7h}$  and  $R^{8h}$ , identical or different, each represent hydrogen or a saturated or unsaturated, optionally at least mono-substituted linear or branched aliphatic radical,

or

$R^{7h}$  and  $R^{8h}$ , together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring

member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

$R^{9h}$  and  $R^{10h}$ , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or

$R^{9h}$  and  $R^{10h}$ , together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

$A^h$  and  $B^h$ , identical or different, each represent a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical

or

$A^h$  and  $B^h$ , together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring,

and

nh is 0, 1, 2, 3 or 4

optionally in the form of one of their stereoisomers, ~~preferably enantiomers or diastereomers~~, their racemate or in the form of a mixture of at least two of their stereoisomers, ~~preferably enantiomers or diastereomers~~, at any mixture ratio, or a corresponding physiologically acceptable salt ~~or a corresponding solvate~~.

Claim 5 (Currently Amended): The combination according to claim 1 or 2 ~~any one of the claims 1 to 4~~, wherein ~~characterized in that~~ it comprises 1-99% by weight of component

(A) and 99-1 % by weight of component (B), ~~more preferably 10-80% by weight of component (A) and 90-20% by weight of component (B)~~, in each case referring to the total weight of both components (A) and (B).

Claim 6 (Currently Amended): A pharmaceutical composition ~~medicament~~ comprising an active substance combination ~~aeording~~ according to claim 1 or 2 ~~any one of the claims 1 to 5~~ and optionally one or more pharmacologically acceptable adjuvants.

Claim 7 (Currently Amended): A pharmaceutical composition ~~medicament~~ according to claim 6, for simultaneous neuropeptide Y- and Y- ~~Y- and~~ 5-HT<sub>6</sub>-receptor regulation, for regulation of appetite, for maintenance, increase or reduction of body weight, for prophylaxis and/or treatment of disorders related to food ingestion, preferably for prophylaxis and/or treatment of obesity, anorexia, cachexia, bulimia, diabetes, preferably type II diabetes (non-insulin-dependent diabetes mellitus), or for prophylaxis and/or treatment of gastrointestinal tract disorders, preferably of the irritable bowel syndrome, for prophylaxis and/or treatment of Peripheral Nervous System Disorders, Central Nervous System Disorders, arthritis, epilepsy, anxiety, panic, depression, cognitive disorders, memory disorders, cardiovascular diseases, senile dementia processes, such as Alzheimer's, Parkinson's and/or Huntington's Disease, schizophrenia, psychosis, infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder), pain, hypertensive syndrome, inflammatoric diseases, immunologic diseases or for improvement of cognition.

Claims 8-33: (Canceled).

Claim 34 (Currently Amended): A pharmaceutical formulation, which ~~characterized in that it~~ comprises an active substance combination according to any one of claims 1 or 2 [[5]] and optionally one or more pharmacologically acceptable adjuvants.

Claim 35 (Currently Amended): The pharmaceutical formulation according to claim 34, which ~~characterized in that it~~ is present in solid pharmaceutical forms such as tablets, tablets, chewing tablets, chewing gums, dragees, capsules, suppositories, powder preparations, transdermal therapeutic systems, transmucosal therapeutic systems, or in liquid and semi-liquid pharmaceutical forms such as drops or such as juice, ~~sirup~~ syrup, solution, emulsion, suspension, preferably in form of tablets, capsules, drops or solution.

Claim 36 (Currently Amended): The pharmaceutical formulation according to claim 34, which ~~characterized in that it~~ is present in form of [[of]] multiple particles, preferably microtablets, microcapsules, microspheroids, granules, crystals or pellets, optionally compacted in a tablet, filled in a capsule or suspended in a suitable liquid.

Claim 37 (Currently Amended): The pharmaceutical formulation according to one or more of claims 34-36, which ~~characterized in that it~~ is for oral, intravenous, intramuscular, subcutaneous, intrathecal, epidural, buccal, sublingual, pulmonal, rectal, transdermal, nasal or intracerebroventricular application, ~~preferably oral or intravenous~~.

Claim 38 (Currently Amended): The pharmaceutical formulation according to one or more of claims 34-36, wherein ~~characterized in that~~ at least one of the components of the active substance combination (A) or (B) is present at least partially in sustained-release form.

Claim 39 (Currently Amended): The pharmaceutical formulation according to claim 38, wherein ~~characterized in that~~ the medicament has at least one coating or at least one matrix comprising at least one material, which sustains active substance release.

Claim 40 (Currently Amended): The pharmaceutical formulation according to claim 39, wherein ~~characterized in that~~ the sustained-release material is based on optionally modified, water-insoluble, natural, semisynthetic or synthetic polymer, or a natural wax or fat or fatty alcohol or semisynthetic or synthetic fatty acid, or on a mixture of at least two of these afore mentioned components.

Claim 41 (Currently Amended): The pharmaceutical formulation according to claim 40, wherein ~~characterized in that~~ the water-insoluble polymer is based on an acrylic resin, which is preferably selected from the group of poly(meth)acrylates, poly(C<sub>1-4</sub>)dialkylamino(C<sub>1-4</sub>)alkyl (meth)acrylates and/or copolymers thereof or a mixture of at least two of the afore-mentioned polymers.

Claim 42 (Currently Amended): The pharmaceutical formulation according to claim 40, wherein ~~characterized in that~~ the water-insoluble polymers are cellulose derivatives, preferably alkyl cellulose and even more preferably ethyl cellulose, or cellulose esters.

Claim 43 (Currently Amended): The pharmaceutical formulation according to claim 40, wherein ~~characterized in that~~ the wax is carnauba wax, beeswax, glycerol monostearate, glycerol monobehenate, glycerol ditripalmitostearate, microcrystalline wax or a mixture of at least two of these components.



Claim 44 (Currently Amended): The pharmaceutical formulation according to one or more of claims 40-43, wherein ~~characterized in that~~ polymers have been used in combination with one or more plasticizers.

Claim 45 (Currently Amended): The pharmaceutical formulation according to one or more of claims 38-44, wherein ~~characterized in that~~ besides the sustained-release form, at least one of the active substance components (A) or (B) is present in a non-sustained-release form.

Claim 46 (New): A method of simultaneously regulating neuropeptide Y5- and 5-HT<sub>6</sub>-receptor, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 47 (New): A method of regulating appetite, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 48 (New): A method of maintaining, increasing or reducing body weight, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 49 (New): A method for prophylaxis and/or treatment of disorders related to food ingestion, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 50 (New): A method for prophylaxis and/or treatment of obesity, anorexia, cachexia, bulimia, diabetes, preferably type II diabetes, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 51 (New): A method for prophylaxis and/or treatment of gastrointestinal tract disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 52 (New): A method for prophylaxis and/or treatment of the irritable bowel syndrome, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 53 (New): A method for prophylaxis and/or treatment of Peripheral Nervous System Disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 54 (New): A method for prophylaxis and/or treatment of Central Nervous System Disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 55 (New): A method for prophylaxis and/or treatment arthritis, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 56 (New): A method for prophylaxis and/or treatment of epilepsy, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 57 (New): A method for prophylaxis and/or treatment of anxiety, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 58 (New): A method for prophylaxis and/or treatment of panic, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 59 (New): A method for prophylaxis and/or treatment of depression comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 60 (New): A method for prophylaxis and/or treatment of bipolar disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 61 (New): A method for prophylaxis and/or treatment of cognitive disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 62 (New): A method for prophylaxis and/or treatment of memory disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 63 (New): A method for prophylaxis and/or treatment of cardiovascular diseases, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 64 (New): A method for prophylaxis and/or treatment of senile dementia processes, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 65 (New): A method for prophylaxis and/or treatment of neurodegenerative disorders, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 66 (New): A method for prophylaxis and/or treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease or multiple sclerosis, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 67 (New): A method for prophylaxis and/or treatment of schizophrenia, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 68 (New): A method for prophylaxis and/or treatment of psychosis, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 69 (New): A method for prophylaxis and/or treatment of infantile hyperkinesia or attention deficit/hyperactivity disorder, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 70 (New): A method for prophylaxis and/or treatment of pain, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 71 (New): A method for prophylaxis and/or treatment of hypertensive syndrome, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 72 (New): A method for prophylaxis and/or treatment of inflammatory diseases, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 73 (New): A method for prophylaxis and/or treatment of immunologic diseases, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.

Claim 74 (New): A method for improving cognition, comprising administering to a subject in need thereof an effective amount of the active substance combination of claim 1 or 2.